May 26, 2022 11:24 AM EDT

Longtime Kadmon consultant slapped with insider trading charges related to $1.9B Sanofi buyout

Nicole DeFeudis

Editor

Months after Sanofi snapped up Kadmon for $1.9 billion, a longtime Kadmon consultant has been accused of using insider knowledge of the buyout to make …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Longtime Kadmon consultant slapped with insider trading charges related to $1.9B Sanofi buyout

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Long­time Kad­mon con­sul­tant slapped with in­sid­er trad­ing charges re­lat­ed to $1.9B Sanofi buy­out

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Longtime Kadmon consultant slapped with insider trading charges related to $1.9B Sanofi buyout

Applied Therapeutics' rare disease drug gets a CRL

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B